Summary

doi: 10.25005/2074-0581-2014-16-1-89-93
Immunological disorders and therapy of patients with traumatic brain injury

E.M. Mamytova

Kyrgyz State Medical Academyim named after IK Ahunbaev, Bishkek, Kyrgyzstan

This paper presents the results of a clinical study, whichaimed to study the influence of drug «Cerebrolysin» on cytokine profile state and cellular immunity in patients in the early posttraumatic period with moderate-to-severe traumatic brain injury (TBI).

Therapy with cerebrolysinled to positive changes of cellular immunity and partial correction T-cell immunodeficiency that occurs after TBI. After 10 days with cerebrolysin treatment there was an increase anti-inflammatory cytokine IL-4 (before treatment 2,0±0,5 pg/L, after – to 2,8±0,4 pg/L), which is 2,1 times higher reference standards, the level of pro-inflammatory cytokines TNF-α (5,8±0,7 pg/ml; 6,2±0,7 pg/l); IL-6 (21,2±5,0%; 28,7±13,6%), which is 3.7 times higher than the physiological limits, and IFN-γ and IL-1 – tended to decrease: IFN-γ – by 79,6±16,2 to 69,3±6,9; IL-1 – 9,1±2,0 pg / ml and 7,3±1,6 pg / ml.

Analysis of T-cell immunity dynamics on 10day after cerebrolysin treatment increase the percentage of CD3+ ( from 34,3±1,4% to 41,2±2,7%) and CD4+ (from 20,4±1,2% up to 21,5±2,2%) subpopulations of T - lymphocytesrevealed.

Cerebrolysinusing in complex treatment of patients with TBI having neuroprotective, neurotrophic and immunomodulatory effects, can reduce the immunosuppression and thus reduce the incidence of septic complications.

Keywords: brain injury, cytokines, lymphocyte subpopulations, cerebrolysin , immunity.

Download file:


Materials on the topic: